Asia Pacific Influenza Treatment Market: Estimation, Dynamics, Country Share, Trends, Competitor Analysis 2016 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

Asia Pacific Influenza Treatment Market By Drug Class (Anti-Viral Drugs, Interferons, Vaccines), By Route of Administration (Oral, Parenteral, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others), and Country

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Categories: ,

Report

Description

Asia Pacific Influenza Treatment Market is expected to grow at a CAGR of 7.1% during the forecast period 2022 to 2028. The global market provides a detailed overview and which can be segmented by drug class, route of administration, and distribution channel. By drug class, the Asia Pacific influenza treatment market has been segmented into anti-viral drugs, interferons, and vaccines. By drug class, the vaccines segment held the largest revenue share of the Asia Pacific influenza treatment market in past years and is expected to have the fastest growth rate over the forecasted period due to the increasing demand for vaccines among a large mass population due to increasing incidences of influenza diseases. By route of administration, the Asia Pacific influenza treatment market has been segmented into oral, parenteral, and others. By route of administration, the oral segment held the largest revenue share market in the past few years and is projected to have the fastest growth rate over the forecasted period due to easy accessibility, and minimum pain.Based on the distribution channel, the segment has been segregated into hospital pharmacies, retail pharmacies, and others. The retail pharmacy segment gained the largest market share in 2021, owing to factors such as the rise in the number of retail pharmacies across the globe. Additionally, some other factors such as a rise in awareness related to the use of influenza drugs further contribute to the growth of the market. Furthermore, the easy availability of influenza drugs surges in the number of retail pharmacies across the globe which further helps to expand the market globally.

Key Development:

In April 2021, Sanofi invested in a leading-edge production site in Singapore; continues to strengthen its vaccine manufacturing capacities.

Asia Pacific Influenza Treatment Market

MARKET SUMMARY
-
7.1%
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 7.1%

Asia Pacific Influenza Treatment Market

  • The asia pacific influenza treatment market report gives comprehensive outlook with special emphasis on key regions such as Japan, China, India, Australia & New Zealand, ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others), South Korea, and Rest of Asia-Pacific.
  • The report on asia pacific influenza treatment market gives historical, current, and future market sizes (US$ Mn) on the basis of product type, by hernia type, end user and region.
Key Players
  • AstraZeneca
  • Hoffmann-La Roche
  • GlaxoSmithKline
  • Novartis AG
  • Sanofi Pasture
Asia Pacific Influenza Treatment Market Drivers

Rising incidences of influenza, increasing awareness, and requirement for new drugs and treatment amid the COVID-19 pandemic. Furthermore, a surge in healthcare expenditure and a rise in R&D investments related to ant-viral drugs boost the influenza treatment market growth. For instance, in 2018, F. Hoffmann-La Roche AG launched Xofluza (Baloxavir Marboxil) for the treatment of influenza.


Asia Pacific Influenza Treatment Market

Asia Pacific market is expected to witness the highest market share during the forecast period owing to a rising aging population, and increasing influenza cases. In addition, technological developments in illness diagnosis, increasing R&D activities to innovate novel therapeutics for treating influenza, frequent product introductions, and government initiatives to increase the consciousness regarding influenza vaccine.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2017-2021) and forecast (2022-2028)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Asia Pacific Influenza Treatment Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

The global Asia Pacific influenza treatment market size is expected to grow at a CAGR of 7.1% during the forecast period 2022 to 2028.

New product launches, and rising research and development activities for the treatment of influenza diseases with reasonable cost.

Investment and acquisition are the two key strategies opted for by the leading players in the market.

The major factors driving the market growth are the rising incidence of influenza cases among a large mass of the population.


Report

Table Of Content

  1. Executive Summary
  2. Asia Pacific Influenza Treatment Market Introduction
    • Asia Pacific Influenza Treatment Market – Taxonomy
    • Asia Pacific Influenza Treatment Market –Definitions
      • Drug Class
      • Route of Administration
      • Distribution Channel
  1. Asia Pacific Influenza Treatment Market Dynamics
    • Drivers
    • Restraints
    • Opportunities/Unmet Needs of the Market
    • Trends
    • Asia Pacific Influenza Treatment Market Dynamic Factors – Impact Analysis
    • Asia Pacific Influenza Treatment Market – Competition Landscape
    • Epidemiology
  2. Asia Pacific Influenza Treatment Market Analysis,2013 – 2017 and Forecast, 2018 – 2024
    • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Year-over-Year (Y-o-Y) Growth Analysis (%)
    • Market OpportunityAnalysis
  3. Asia Pacific Influenza Treatment Market, By Drug Class, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Anti-viral drugs
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Zanamivir
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Oseltamivir
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Amantadine
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Rimantadine
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Others
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Interferons
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Vaccines
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Trivalent
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Quadrivalent
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Asia Pacific Influenza Treatment Market Forecast, By Route of Administration,2013 – 2017 and Forecast, 2018 – 2024
    • Oral
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Anti-viral drugs
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Parenteral
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Interferon alfa-2b
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Others
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Asia Pacific Influenza Treatment Market Forecast, By Distribution Channel, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Hospital Pharmacies
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Retail Pharmacies
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Others
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Asia Pacific Influenza Treatment Market Forecast, By Country, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Japan
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • China
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • India
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Australia & New Zealand
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • ASEAN
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • South Korea
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Rest of Asia Pacific
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Asia Pacific Influenza Treatment Market – Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel and Country, 2018 – 2024
  2. Japan Influenza Treatment Market Analysis,2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Anti-viral drugs
      • Zanamivir
      • Oseltamivir
      • Amantadine
      • Rimantadine
      • Others
      • Interferons
      • Vaccines
      • Trivalent
      • Quadrivalent
    • Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Anti-viral drugs
      • Parenteral
      • Interferon alfa-2b
      • Others
    • Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Others
    • Japan Influenza Treatment Market – Opportunity Analysis Index, By Drug Class, By Route of Administration and By Distribution Channel, 2018 – 2024
    • Japan Influenza Treatment Market Dynamics – Trends
  3. China Influenza Treatment Market Analysis,2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Anti-viral drugs
      • Zanamivir
      • Oseltamivir
      • Amantadine
      • Rimantadine
      • Others
      • Interferons
      • Vaccines
      • Trivalent
      • Quadrivalent
    • Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Anti-viral drugs
      • Parenteral
      • Interferon alfa-2b
      • Others
    • Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Others
    • China Influenza Treatment Market – Opportunity Analysis Index, By Drug Class, By Route of Administration and By Distribution Channel, 2018 – 2024
    • China Influenza Treatment Market Dynamics – Trends
  4. India Influenza Treatment Market Analysis,2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Anti-viral drugs
      • Zanamivir
      • Oseltamivir
      • Amantadine
      • Rimantadine
      • Others
      • Interferons
      • Vaccines
      • Trivalent
      • Quadrivalent
    • Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Anti-viral drugs
      • Parenteral
      • Interferon alfa-2b
      • Others
    • Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Others
    • India Influenza Treatment Market – Opportunity Analysis Index, By Drug Class, By Route of Administration and By Distribution Channel, 2018 – 2024
    • India Influenza Treatment Market Dynamics – Trends
  5. Australia & New Zealand Influenza Treatment Market Analysis,2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Anti-viral drugs
      • Zanamivir
      • Oseltamivir
      • Amantadine
      • Rimantadine
      • Others
      • Interferons
      • Vaccines
      • Trivalent
      • Quadrivalent
    • Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Anti-viral drugs
      • Parenteral
      • Interferon alfa-2b
      • Others
    • Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Others
    • Australia & New Zealand Influenza Treatment Market – Opportunity Analysis Index, By Drug Class, By Route of Administration and By Distribution Channel, 2018 – 2024
    • Australia & New Zealand Influenza Treatment Market Dynamics – Trends
  6. ASEAN Influenza Treatment Market Analysis,2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Anti-viral drugs
      • Zanamivir
      • Oseltamivir
      • Amantadine
      • Rimantadine
      • Others
      • Interferons
      • Vaccines
      • Trivalent
      • Quadrivalent
    • Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Anti-viral drugs
      • Parenteral
      • Interferon alfa-2b
      • Others
    • Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Others
    • ASEAN Influenza Treatment Market – Opportunity Analysis Index, By Drug Class, By Route of Administration and By Distribution Channel, 2018 – 2024
    • ASEAN Influenza Treatment Market Dynamics – Trends
  7. South Korea Influenza Treatment Market Analysis,2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Anti-viral drugs
      • Zanamivir
      • Oseltamivir
      • Amantadine
      • Rimantadine
      • Others
      • Interferons
      • Vaccines
      • Trivalent
      • Quadrivalent
    • Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Anti-viral drugs
      • Parenteral
      • Interferon alfa-2b
      • Others
    • Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Others
    • South Korea Influenza Treatment Market – Opportunity Analysis Index, By Drug Class, By Route of Administration and By Distribution Channel, 2018 – 2024
    • South Korea Influenza Treatment Market Dynamics – Trends
  8. Rest of Asia Pacific Influenza Treatment Market Analysis,2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Anti-viral drugs
      • Zanamivir
      • Oseltamivir
      • Amantadine
      • Rimantadine
      • Others
      • Interferons
      • Vaccines
      • Trivalent
      • Quadrivalent
    • Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Anti-viral drugs
      • Parenteral
      • Interferon alfa-2b
      • Others
    • Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Others
    • Rest of Asia Pacific Influenza Treatment Market – Opportunity Analysis Index, By Drug Class, By Route of Administration and By Distribution Channel, 2018 – 2024
    • Rest of Asia Pacific Influenza Treatment Market Dynamics – Trends
  9. Competition Landscape
    • Strategic Dashboard of Top Market Players
    • Company Profiles (Introduction, Financial Analysis, Drug Class& Service Offerings, Key Developments, Strategies, and SWOT Analysis)
      • AstraZeneca (U.K.)
      • Hoffmann-La Roche (Switzerland)
      • GlaxoSmithKline Plc. (U.K.)
      • Novartis AG (Switzerland)
      • Sanofi Pasture (France)
      • Protein Sciences Corporation (U.S.)
      • Emergent Biosolutions (U.S.)
      • BioCryst Pharmaceuticals.Inc. (U.S.)
      • Shionogi Inc. (Japan)
      • Abbott Laboratories Inc. (U.S.)
  1. Research Methodology
  2. Key Assumptions and Acronyms

 


Report

Company Profile

  • AstraZeneca (U.K.)
  • Hoffmann-La Roche (Switzerland)
  • GlaxoSmithKline Plc. (U.K.)
  • Novartis AG (Switzerland)
  • Sanofi Pasture (France)
  • Protein Sciences Corporation (U.S.)
  • Emergent Biosolutions (U.S.)
  • BioCryst Pharmaceuticals.Inc. (U.S.)
  • Shionogi Inc. (Japan)
  • Abbott Laboratories Inc. (U.S.)

Description

Asia Pacific Influenza Treatment Market is expected to grow at a CAGR of 7.1% during the forecast period 2022 to 2028. The global market provides a detailed overview and which can be segmented by drug class, route of administration, and distribution channel. By drug class, the Asia Pacific influenza treatment market has been segmented into anti-viral drugs, interferons, and vaccines. By drug class, the vaccines segment held the largest revenue share of the Asia Pacific influenza treatment market in past years and is expected to have the fastest growth rate over the forecasted period due to the increasing demand for vaccines among a large mass population due to increasing incidences of influenza diseases. By route of administration, the Asia Pacific influenza treatment market has been segmented into oral, parenteral, and others. By route of administration, the oral segment held the largest revenue share market in the past few years and is projected to have the fastest growth rate over the forecasted period due to easy accessibility, and minimum pain.Based on the distribution channel, the segment has been segregated into hospital pharmacies, retail pharmacies, and others. The retail pharmacy segment gained the largest market share in 2021, owing to factors such as the rise in the number of retail pharmacies across the globe. Additionally, some other factors such as a rise in awareness related to the use of influenza drugs further contribute to the growth of the market. Furthermore, the easy availability of influenza drugs surges in the number of retail pharmacies across the globe which further helps to expand the market globally.

Key Development:

In April 2021, Sanofi invested in a leading-edge production site in Singapore; continues to strengthen its vaccine manufacturing capacities.

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX